MRI of Bladder Cancer: Local and Nodal Staging.
bladder cancer (BC)
multiparametric MRI
staging
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
18
12
2019
revised:
20
01
2020
accepted:
21
01
2020
pubmed:
1
3
2020
medline:
15
5
2021
entrez:
1
3
2020
Statut:
ppublish
Résumé
Accurate staging of bladder cancer (BC) is critical, with local tumor staging directly influencing management decisions and affecting prognosis. However, clinical staging based on clinical examination, including cystoscopy and transurethral resection of bladder tumor (TURBT), often understages patients compared to final pathology at radical cystectomy and lymph node (LN) dissection, mainly due to underestimation of the depth of local invasion and the presence of LN metastasis. MRI has now become established as the modality of choice for the local staging of BC and can be additionally utilized for the assessment of regional LN involvement and tumor spread to the pelvic bones and upper urinary tract (UUT). The recent development of the Vesical Imaging-Reporting and Data System (VI-RADS) recommendations has led to further improvements in bladder MRI, enabling standardization of image acquisition and reporting. Multiparametric magnetic resonance imaging (mpMRI) incorporating morphological and functional imaging has been proven to further improve the accuracy of primary and recurrent tumor detection and local staging, and has shown promise in predicting tumor aggressiveness and monitoring response to therapy. These sequences can also be utilized to perform radiomics, which has shown encouraging initial results in predicting BC grade and local stage. In this article, the current state of evidence supporting MRI in local, regional, and distant staging in patients with BC is reviewed. LEVEL OF EVIDENCE: 3 TECHNICAL EFFICACY STAGE: 2 J. Magn. Reson. Imaging 2020;52:649-667.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-667Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2020 International Society for Magnetic Resonance in Medicine.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.
Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: Role of MR imaging. Radiographics 2012;32:371-387.
Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: What are the benefits and costs? World J Urol 2009;27:295-300.
Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 2017;71:447-461.
Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017;71:462-475.
Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: Development of VI-RADS (vesical imaging-reporting and data system). Eur Urol 2018;74:294-306.
Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005;95:786-790.
Dutta SC, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-493.
Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The diagnostic value of MR imaging in differentiating t staging of bladder cancer: A meta-analysis. Radiology 2018;286:502-511.
Gandhi N, Krishna S, Booth CM, et al. Diagnostic accuracy of magnetic resonance imaging for tumor staging of bladder cancer: Systematic review and meta-analysis. BJU Int 2018;122:744-753.
Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. Eur J Radiol 2017;95:46-55.
De Haas RJ, Steyvers MJ, Fütterer JJ. Multiparametric MRI of the bladder: Ready for clinical routine? Am J Roentgenol 2014;202:1187-1195.
Barchetti G, Simone G, Ceravolo I, et al. Multiparametric MRI of the bladder: Inter-observer agreement and accuracy with the vesical imaging-reporting and data system (VI-RADS) at a single reference center. Eur Radiol 2019;29:5498-5506.
Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH. Diffusion-weighted MRI in bladder carcinoma: The differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 2014;39:135-141.
Nguyen HT, Jia G, Shah ZK, et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 2015;41:1374-1382.
Nguyen HT, Mortazavi A, Pohar KS, et al. Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: Can response be predicted prior to neoadjuvant chemotherapy? Bladder Cancer 2017;3:237-244.
Woo S, Suh CH, Kim SY, Cho JY, Kim SH. The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: An updated systematic review and diagnostic meta-analysis. Am J Roentgenol 2018;210:W95-W109.
Sudah M, Masarwah A, Kainulainen S, et al. Comprehensive MR urography protocol: Equally good diagnostic performance and enhanced visibility of the upper urinary tract compared to triple-phase CT urography. PLoS One 2016;11:1-12.
Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology 2019;74:112-134.
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
Brierley J, Gospodarowicz MD, Wittekind CT. TNM classification of malignant tumors. International union against cancer. 8th ed.Hoboken, NJ: Wiley; 2017.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumors of the urinary system and male genital organs-Part B: Prostate and bladder tumors. Eur Urol 2016;70:106-119.
Lawler LP. MR imaging of the bladder. Radiol Clin North Am 2003;41:161-177.
Takeuchi M, Sasaki S, Naiki T, et al. MR imaging of urinary bladder cancer for T-staging: A review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging 2013;38:1299-1309.
Mirmomen SM, Shinagare AB, Williams KE, Silverman SG, Malayeri AA. Preoperative imaging for locoregional staging of bladder cancer. Abdom Radiol 2019;44:3843-3857.
Panebianco V, Barchetti F, de Haas RJ, et al. Improving staging in bladder cancer: The increasing role of multiparametric magnetic resonance imaging. Eur Urol Focus 2016;2:113-121.
Caglic I, Povalej Brzan P, Warren AY, Bratt O, Shah N, Barrett T. Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. Eur Radiol 2019;29:5488-5497.
Kim H, Lim JS, Choi JY, et al. Rectal cancer: Comparison of accuracy of local-regional staging with two- and three-dimensional preoperative 3-T MR imaging. Radiology 2010;254:485-492.
Zhou G, Chen X, Zhang J, Zhu J, Zong G, Wang Z. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol 2014;83:2013-2018.
Kobayashi S, Koga F, Kajino K, et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging 2014;39:172-178.
Rosenkrantz AB, Obele C, Rusinek H, et al. Whole-lesion diffusion metrics for assessment of bladder cancer aggressiveness. Abdom Imaging 2015;40:327-332.
Sevcenco S, Ponhold L, Heinz-Peer G, et al. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urol Oncol 2014;32:1166-1171.
Lin W-C, Chen J-H. Pitfalls and limitations of diffusion-weighted magnetic resonance imaging in the diagnosis of urinary bladder cancer. Transl Oncol 2015;8:217-230.
Donaldson SB, Bonington SC, Kershaw LE, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumor and post-chemotherapy effect. Eur J Radiol 2013;82:2161-2168.
Narumi Y, Kadota T, Inoue E, et al. Bladder tumors: Staging with gadolinium-enhanced oblique MR imaging. Radiology 1993;187:145-150.
Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: Evaluation of staging accuracy. Am J Roentgenol 2005;184:121-127.
Altun E. MR imaging of the urinary bladder: Added value of PET-MR imaging. Magn Reson Imaging Clin N Am 2019;27:105-115.
van der Pol CB, Chung A, Lim C, et al. Update on multiparametric MRI of urinary bladder cancer. J Magn Reson Imaging 2018;48:882-896.
Barentsz JO, Ruijs SHJ, Strijk SP. The role of MR imaging in carcinoma of the urinary bladder. Am J Roentgenol 1993;160:937-947.
Sushentsev N, Tanner J, Slough RA, Kozlov V, Gill AB, Barrett T. The effect of different drinking and voiding preparations on magnetic resonance imaging bladder distention in normal volunteers and patients. Can Assoc Radiol J 2018;69:383-389.
Slough RA, Caglic I, Hansen NL, Patterson AJ, Barrett T. Effect of hyoscine butylbromide on prostate multiparametric MRI anatomical and functional image quality. Clin Radiol 2018;73:216.e9-216.e14.
Johnson W, Taylor MB, Carrington BM, Bonington SC, Swindell R. The value of hyoscine butylbromide in pelvic MRI. Clin Radiol 2007;62:1087-1093.
Caglic I, Barrett T. Optimising prostate mpMRI: Prepare for success. Clin Radiol 2019;74:831-840.
Huang SY, Seethamraju RT, Patel P, Hahn PF, Kirsch JE, Guimaraes AR. Body MR imaging: Artifacts, k-space, and solutions. Radiographics 2015;35:1439-1460.
Fujimoto K, Koyama T, Tamai K, Morisawa N, Okada T, Togashi K. BLADE acquisition method improves T2-weighted MR images of the female pelvis compared with a standard fast spin-echo sequence. Eur J Radiol 2011;80:796-801.
Lane BF, Vandermeer FQ, Oz RC, Irwin EW, McMillan AB, Wong-You-Cheong JJ. Comparison of sagittal T2-weighted BLADE and fast spin-echo MRI of the female pelvis for motion artifact and lesion detection. Am J Roentgenol 2011;197:W307-W313.
Froehlich JM, Metens T, Chilla B, Hauser N, Klarhoefer M, Kubik-Huch RA. Should less motion sensitive T2-weighted BLADE TSE replace Cartesian TSE for female pelvic MRI? Insights Imaging 2012;3:611-618.
Zaitsev M, Maclaren J, Herbst M. Motion artifacts in MRI: A complex problem with many partial solutions. J Magn Reson Imaging 2015;42:887-901.
Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: Comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193:239-245.
Gordon PC, Thomas F, Noon AP, Rosario DJ, Catto JWF. Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: A potential to rationalize use. Eur Urol Focus 2019;5:650-657.
Thomas F, Noon AP, Rubin N, Goepel JR, Catto JWF. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol 2013;63:145-154.
Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: Impact on prognosis after radical cystectomy. Eur Urol 2007;51:137-151.
Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: Diffusion-weighted MR imaging-Accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251:112-121.
Panebianco V, De Berardinis E, Barchetti G, et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 2017;27:3759-3766.
Lee CH, Tan CH, Faria S de C, Kundra V. Role of imaging in the local staging of urothelial carcinoma of the bladder. Am J Roentgenol 2017;208:1193-1205.
Barrett T, Turkbey B, Choyke PL. PI-RADS version 2: What you need to know. Clin Radiol 2015;70:1165-1176.
Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289:816-830.
Wang H, Luo C, Zhang F, et al. Multiparametric MRI for bladder cancer: Validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 2019;291:668-674.
Kim SH. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol 2019;45(2):491-498.
Ueno Y, Takeuchi M, Tamada T, et al. Diagnostic accuracy and interobserver agreement for the vesical imaging-reporting and data system for muscle-invasive bladder cancer: A multireader validation study. Eur Urol 2019;76:54-56.
Del Giudice F, Barchetti G, De Berardinis E, et al. Prospective assessment of vesical imaging reporting and data system (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur Urol 2020;77:101-109.
Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 2006;176:493-499.
Vikram R, Sandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: Part 1, lower urinary tract. Am J Roentgenol 2009;192:1481-1487.
Daneshmand S, Stein JP, Lesser T, et al. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol 2004;172:81-84.
Sureka B, Kumar M, Malik A, Bhushan T, Mohanty N, Gupta N. Comparison of dynamic contrast-enhanced and diffusion weighted magnetic resonance image in staging and grading of carcinoma bladder with histopathological correlation. Urol Ann 2015;7:199-204.
Dutta R, Abdelhalim A, Martin JW, et al. Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urol Oncol 2016;34:531.e1-531.e6.
Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol 2016;13:471-479.
Horn T, Zahel T, Adt N, et al. Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy. Urol Int 2016;96:51-56.
Wiesner C, Salzer A, Thomas C, et al. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: Prediction by lymph node positivity and density. BJU Int 2009;104:331-335.
Macvicar AD. Bladder cancer staging. BJU Int 2000;86(Suppl 1):111-122.
Simone G, Papalia R, Ferriero M, et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol 2013;20:390-397.
Svatek RS, Clinton TN, Wilson CA, et al. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology 2014;84:1147-1151.
Dorin RP, Daneshmand S, Eisenberg MS, et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: A comparative mapping study. Eur Urol 2011;60:946-952.
Paño B, Sebastià C, Buñesch L, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics 2011;31:135-160.
Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M, Ghoneim MA. Lymph node involvement in patients with bladder cancer treated with radical cystectomy: A patho-anatomical study-A single center experience. J Urol 2004;172:1818-1821.
Zlotta AR. Limited, extended, superextended, megaextended pelvic lymph node dissection at the time of radical cystectomy: What should we perform? Eur Urol 2012;61:243-244.
Salminen AP, Jambor I, Syvänen KT, Boström PJ. Update on novel imaging techniques for the detection of lymph node metastases in bladder cancer. Minerva Urol Nefrol 2016;68(2):138-149.
Thoeny HC, Froehlich JM, Triantafyllou M, et al. Metastases in normal-sized pelvic lymph nodes: Detection with diffusion-weighted MR imaging. Radiology 2014;273:125-135.
Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990;144(2 Part 1):243-245.
von Below C, Daouacher G, Wassberg C, et al. Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clin Radiol 2016;71:328-334.
Caglic I, Barrett T. Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer. Transl Androl Urol 2018;7:814-823.
Kwee TC, Takahara T, Luijten PR, Nievelstein RAJ. ADC measurements of lymph nodes: Inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 2010;75:215-220.
Braithwaite AC, Dale BM, Boll DT, Merkle EM. Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 2009;250:459-465.
Muenzel D, Duetsch S, Fauser C, et al. Diffusion-weighted magnetic resonance imaging in cervical lymphadenopathy: Report of three cases of patients with Bartonella henselae infection mimicking malignant disease. Acta Radiol 2009;50:914-916.
Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: Image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011;33:128-135.
Abdel Razek AAK, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006;16:1468-1477.
Sushentsev N, Martin H, Rimmer Y, Barrett T. Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies. Clin Transl Oncol 2019;21:1383-1389.
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499.
Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009;55:761-769.
Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013;64:953-960.
Fortuin AS, Brüggemann R, van der Linden J, et al. Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: Back on the block. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018;10:e1471.
Chung AD, Schieda N, Shanbhogue AK, Dilauro M, Rosenkrantz AB, Siegelman ES. MRI evaluation of the urothelial tract: Pitfalls and solutions. Am J Roentgenol 2016;207:W108-W116.
Silverman SG, Leyendecker JR, Amis ES. What is the current role of CT urography and MR urography in the evaluation of the urinary tract? Radiology 2009;250:309-323.
Heidenreich A, Albers P, Classen J, et al. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: Recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 2010;85:1-10.
Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174:14-20.
Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: Evaluation of patients for metastases. Radiology 2004;233:139-148.
Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: The value of MR imaging. Skeletal Radiol 2007;36:1109-1119.
Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: Current status and research directions. Radiology 2011;261:700-718.
Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin M-E, Van den Abbeele AD. Metastatic pattern of bladder cancer: Correlation with the characteristics of the primary tumor. Am J Roentgenol 2011;196:117-122.
Takeuchi M, Suzuki T, Sasaki S, et al. Clinicopathologic significance of high signal intensity on diffusion-weighted MR imaging in the ureter, urethra, prostate and bone of patients with bladder cancer. Acad Radiol 2012;19:827-833.
Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Overview of bladder cancer trials in the radiation therapy oncology group. Cancer 2003;97:2115-2119.
Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115:4104-4109.
Necchi A, Mariani L, Giannatempo P, et al. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. Clin Genitourin Cancer 2014;12:203-209.e1.
Vargas HA, Akin O, Schöder H, et al. Prospective evaluation of MRI, 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol 2012;81:4131-4137.
Chin J, Kadhim S, Garcia B, Kim YS, Karlik S. Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol 1991;145:1297-1301.
Mazurchuk R, Glaves D, Raghavan D. Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer. Clin Cancer Res 1997;3(9):1635-1641.
Yoshida S, Koga F, Kobayashi S, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012;83:e21-e27.
Motterle G, Andrews JR, Morlacco A, Karnes RJ. Predicting response to neoadjuvant chemotherapy in bladder cancer. Eur Urol Focus 2019;5:271-273.
Barentsz JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998;207:791-797.
Schrier BP, Peters M, Barentsz JO, Witjes JA. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006;49:698-703.
Chakiba C, Cornelis F, Descat E, et al. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. Eur J Radiol 2015;84:1023-1028.
Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32:1889-1894.
Xu X, Liu Y, Zhang X, et al. Preoperative prediction of muscular invasiveness of bladder cancer with radiomic features on conventional MRI and its high-order derivative maps. Abdom Radiol (NY) 2017;42:1896-1905.
Zhang X, Xu X, Tian Q, et al. Radiomics assessment of bladder cancer grade using texture features from diffusion-weighted imaging. J Magn Reson Imaging 2017;46:1281-1288.
Tong Y, Udupa JK, Wang C, et al. Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. Adv Radiat Oncol 2018;3:331-338.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data. Radiology 2016;278:563-577.